Celcuity (7VR) Stock Overview
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
7VR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Celcuity Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$80.00 |
| 52 Week High | US$89.00 |
| 52 Week Low | US$11.48 |
| Beta | 0.22 |
| 1 Month Change | -5.33% |
| 3 Month Change | 81.00% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 595.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7VR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.9% | 0.2% | 0.7% |
| 1Y | n/a | -30.8% | 14.2% |
Return vs Industry: Insufficient data to determine how 7VR performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 7VR performed against the German Market.
Price Volatility
| 7VR volatility | |
|---|---|
| 7VR Average Weekly Movement | 28.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7VR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 7VR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 87 | Brian Sullivan | www.celcuity.com |
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform.
Celcuity Inc. Fundamentals Summary
| 7VR fundamental statistics | |
|---|---|
| Market cap | €4.03b |
| Earnings (TTM) | -€138.13m |
| Revenue (TTM) | n/a |
Is 7VR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7VR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$162.72m |
| Earnings | -US$162.72m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 273.8% |
How did 7VR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/25 03:19 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celcuity Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arlinda Lee | Canaccord Genuity |
| Alexander Nowak | Craig-Hallum Capital Group LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |